GlaxoSmithKline to cease providing corporate political contributions
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future.
Glivec shows significant benefit for gastrointestinal stromal tumor (GIST) patients
- Details
- Category: Novartis
Glivec® (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).
AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration
- Details
- Category: AstraZeneca
AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for paediatric asthma and is currently in Phase III clinical development.
First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
- Details
- Category: Abbott
The U.S. Food and Drug Administration (FDA) has approved Abbott's TRILIPIX(TM) (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL cholesterol, and to raise HDL cholesterol in patients with lipid problems.
Bayer innovations provide solutions for the global challenges of the future
- Details
- Category: Bayer
The Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. "The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success," said Werner Wenning, Chairman of the Board of Management of Bayer AG, in an address given in front of 130 journalists during the "Bayer's Perspective on Innovation 2008" press forum in Leverkusen.
Roche and Axiogenesis Enter into Co-Development and Marketing Agreement
- Details
- Category: Roche
Roche and Axiogenesis AG, Cologne, Germany have entered into an agreement for the development and distribution for Axiogenesis' Cor.At(R) 100% pure cardiomyocytes platform as an integral part of the xCELLigence life cell analysis system. Under the terms of the agreement, RAS will market cell-systems, based on the technology of Axiogenesis Cor.At being customize for the xCELLigence platform.
Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria
- Details
- Category: Pfizer
Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim®, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.
More Pharma News ...
- AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration
- GSK analysis shows Seretide/Advair is a well tolerated and effective medicine
- Bayer Schering Pharma expands men's healthcare portfolio
- Children in the world's poorest countries to get free insulin
- Roche signs definitive agreement to acquire Memory Pharmaceuticals
- Pfizer's Novel HIV/AIDS Treatment SELZENTRY™
- AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva